Year All 2026 2025 2024 2023 2022 2019 Date Title Download August 31, 2026 AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting August 24, 2026 AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer August 11, 2026 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights June 4, 2026 AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease May 21, 2026 AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference May 11, 2026 AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights May 7, 2026 AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum March 31, 2026 AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease March 17, 2026 AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights March 9, 2026 AN2 Therapeutics Announces $40 Million Private Placement Financing